Part:BBa_K5063001

Lupin beans are yellow legume seeds from the lupinus albus plant mostly found in the Mediterranean countries. They are a considered a super bean because of all the health benefits that are packed inside the small bean. The lupin bean exceeds most other beans in its fiber content making them perfect for preventing many heart-related diseases.

Lupin peptide P5 are natural peptides, deriving from the hydrolysis of lupin protein and absorbable at intestinal level, are able to inhibit the protein-protein interaction between PCSK9 and the low density lipoprotein receptor (LDLR).

Lupin Peptide P5 Function Lupin peptide P5 has emerged as a promising candidate in cholesterol management, exhibiting statin-like properties through its competitive inhibition of HMG-CoA reductase. By targeting this crucial enzyme in the mevalonate pathway, Lupin peptide P5 plays a significant role in reducing cholesterol production and enhancing the uptake of low-density lipoprotein (LDL) particles. This exploration delves deeper into its mechanisms of action and its interaction with PCSK9, along with the implications for cardiovascular health.

Mechanism of HMG-CoA Reductase Inhibition HMG-CoA reductase catalyses the conversion of HMG-CoA to mevalonate, a pivotal step in cholesterol biosynthesis. By inhibiting this enzyme, Lupin peptide P5 effectively decreases the synthesis of mevalonate, leading to a cascade of metabolic changes. The reduction in mevalonate has several downstream effects. First, lower levels of mevalonate directly correlate with diminished cholesterol synthesis within the liver. This reduction not only lowers overall cholesterol levels but also impacts the production of very-low-density lipoprotein (VLDL), a precursor to LDL.

In addition, the decline in cholesterol levels triggers a compensatory mechanism in the liver, where the expression of LDL receptors (LDLr) is upregulated. This increase in LDLr on the cell surface enhances the liver’s capacity to clear LDL from circulation, resulting in reduced plasma LDL levels. Thus, the inhibition of HMG-CoA reductase by Lupin peptide P5 is a foundational mechanism in lowering cholesterol levels.

Role of PCSK9 in Cholesterol Regulation Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL receptor levels. It functions by binding to the LDLr, which facilitates its degradation and reduces the receptor's availability for LDL uptake. When PCSK9 binds to the LDLr along with LDL particles, the complex is internalised into the cell. However, instead of separating the LDL from the LDLr, PCSK9 promotes the degradation of the entire complex in the lysosome. This results in fewer LDL receptors being recycled back to the cell surface, leading to a decrease in LDL uptake and an increase in cholesterol levels in the bloodstream.

Lupin Peptide P5’s Action Against PCSK9 Lupin peptide P5’s ability to counteract the detrimental effects of PCSK9 is a noteworthy aspect of its mechanism. By binding to PCSK9, Lupin peptide P5 prevents the formation of the PCSK9-LDLr complex, allowing for the normal endocytosis of LDL particles to be maintained. With PCSK9 inhibited, LDL receptors can effectively bind and internalise LDL particles from the bloodstream, restoring normal uptake processes. Furthermore, since PCSK9 is unable to facilitate the degradation of the LDLr, these receptors can be recycled back to the cell surface, thereby increasing the liver's capacity to clear LDL and further reducing plasma cholesterol levels.

The dual action of Lupin peptide P5—both inhibiting HMG-CoA reductase and blocking PCSK9—positions it as a potential adjunct to existing cholesterol-lowering therapies, such as statins and PCSK9 inhibitors. This combination could yield synergistic effects, optimising cholesterol management and enhancing cardiovascular protection.